Effects of SGLT2 inhibitors on UTIs and genital infections in type 2 diabetes mellitus: a systematic review and meta-analysis

被引：172

作者：

Liu, Jiali ^{[1
]}

Li, Ling ^{[1
]}

Li, Sheyu ^{[2
]}

Jia, Pengli ^{[1
]}

Deng, Ke ^{[1
]}

Chen, Wenwen ^{[1
]}

Sun, Xin ^{[1
]}

机构：

[1] Sichuan Univ, West China Hosp, Chinese Evidence Based Med Ctr, Chengdu, Sichuan, Peoples R China

[2] Sichuan Univ, West China Hosp, Dept Endocrinol & Metab, Chengdu, Sichuan, Peoples R China

来源：

SCIENTIFIC REPORTS | 2017年 / 7卷

基金：

中国国家自然科学基金;

关键词：

COTRANSPORTER; 2; INHIBITORS; DOUBLE-BLIND; JAPANESE PATIENTS; SAFETY; EFFICACY; LUSEOGLIFLOZIN; EMPAGLIFLOZIN; CANAGLIFLOZIN; OUTCOMES; TRIALS;

D O I：

10.1038/s41598-017-02733-w

中图分类号：

O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];

学科分类号：

07 ; 0710 ; 09 ;

摘要：

Previous trial evidence suggested potential risk of serious urinary tract infections (UTIs) and genital infections in type 2 diabetes patients using sodium glucose co-transporter-2 inhibitors (SGLT2) inhibitors. We conducted a systematic review and meta-analysis to assess the effects of SGLT2 inhibitors on UTIs and genital infections in patients with type 2 diabetes. In total, 77 RCTs involving 50,820 participants were eligible. The meta-analyses of randomized controlled trials (RCTs) showed no significant difference in UTIs between SGLT2 inhibitors versus control (2,526/29,086 vs. 1,278/14,940; risk ratio (RR) 1.05, 95% confidence interval (CI) 0.98 to 1.12; moderate quality evidence), but suggested increased risk of genital infections with SGLT2 inhibitors (1,521/24,017 vs. 216/12,552; RR 3.30, 95% CI 2.74 to 3.99; moderate quality evidence). Subgroup analyses by length of follow up (interaction p = 0.005), type of control (interaction p = 0.04) and individual SGLT2 inhibitors (interaction p = 0.03) also showed statistically significant differences in genital infections. The upcoming major trials may provide important additional insights on UTIs, and more efforts are needed to address comparative effects of each individual SGLT2 inhibitors on the infections.

引用

页数：11

共 34 条

[1] Specific instructions for estimating unclearly reported blinding status in randomized trials were reliable and valid [J].

Akl, Elie A. ;

Sun, Xin ;

Busse, Jason W. ;

Johnston, Bradley C. ;

Briel, Matthias ;

Mulla, Sohail ;

You, John J. ;

Bassler, Dirk ;

Lamontagne, Francois ;

Vera, Claudio ;

Alshurafa, Mohamad ;

Katsios, Christina M. ;

Heels-Ansdell, Diane ;

Zhou, Qi ;

Mills, Ed ;

Guyatt, Gordon H. .

JOURNAL OF CLINICAL EPIDEMIOLOGY, 2012, 65 (03) :262-267

[2]

[Anonymous], 2015, FDA DRUG SAF COMM FD

[3]

AstraZeneca B-M Squibb The TIMI Study Group Hadassah Medical Organization, 2000, MULT TRIAL EV EFF DA

[4] Influence of diabetes and hyperglycaemia on infectious disease hospitalisation and outcome [J].

Benfield, T. ;

Jensen, J. S. ;

Nordestgaard, B. G. .

DIABETOLOGIA, 2007, 50 (03) :549-554

[5] Sodium glucose co-transport 2 inhibitors in the treatment of type 2 diabetes mellitus: a meta-analysis of randomized double-blind controlled trials [J].

Berhan, Asres ;

Barker, Alex .

BMC ENDOCRINE DISORDERS, 2013, 13

[6] SGLT2 inhibitors [J].

Dardi, I. ;

Kouvatsos, T. ;

Jabbour, S. A. .

BIOCHEMICAL PHARMACOLOGY, 2016, 101 :27-39

[7]

European Medicines Agency, 2013, EPAR SUMM PUBL EMEA

[8]

European Medicines Agency, 2012, EPAR SUMM PUBL EMEA

[9]

European Medicines Agency, 2014, EPAR SUMM PUBL EMEA

[10] Genital and urinary tract infections in diabetes: Impact of pharmacologically-induced glucosuria [J].

Geerlings, Suzanne ;

Fonseca, Vivian ;

Castro-Diaz, David ;

List, James ;

Parikh, Shamik .

DIABETES RESEARCH AND CLINICAL PRACTICE, 2014, 103 (03) :373-381

← 1 2 3 4 →